{
    "id": 26406,
    "fullName": "CD33 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD33 positive indicates the presence of the CD33 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 945,
        "geneSymbol": "CD33",
        "terms": [
            "CD33",
            "p67",
            "SIGLEC-3",
            "SIGLEC3"
        ]
    },
    "variant": "positive",
    "createDate": "04/19/2017",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12702,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the CD33-targeted antibody-drug conjugate Lintuzumab-Ac225 in combination with low dose Cytosar-U (cytarabine) resulted in an objective response rate of 28% (5/18), a median progression-free survival of 2.7 months, a median overall survival of 5.6 months, and a median response duration of 5.6 months in patients with untreated acute myeloid leukemia (Blood 2016 128:4050).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 6593,
                "therapyName": "Lintuzumab-Ac225",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10611,
                    "pubMedId": null,
                    "title": "Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)",
                    "url": "http://www.bloodjournal.org/content/128/22/4050?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20820,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line xenograft model of acute promyelocytic leukemia expressing CD33 and consisting of human natural killer cells treated with GTB-3550 TriKE reduced tumor burden (PMID: 26847056).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 9469,
                "therapyName": "GTB-3550 TriKE",
                "synonyms": null
            },
            "indication": {
                "id": 60318,
                "name": "acute promyelocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18074,
                    "pubMedId": 26847056,
                    "title": "IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26847056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10952,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG-564 induced cytotoxicity of CD33-positive acute myeloid leukemia (AML) cells in culture, and inhibited tumor growth in a CD33-positive AML cell line xenograft model (PMID: 27189165).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 5711,
                "therapyName": "AMV-564",
                "synonyms": null
            },
            "indication": {
                "id": 8747,
                "name": "subacute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8953,
                    "pubMedId": 27189165,
                    "title": "Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27189165"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15003,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 330 treatment resulted in complete lysis of CD33-positive acute myeloid leukemia cell lines in culture, and prolonged survival in cell line xenograft models (PMID: 24674885).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 7379,
                "therapyName": "AMG 330",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12061,
                    "pubMedId": 24674885,
                    "title": "Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24674885"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12025,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Mylotarg (gemtuzumab ozogamicin) was well-tolerated and improved overall survival compared to best supportive care (4.9 mo vs. 3.6 mo; HR=0.69, p=0.005) in patients with CD33-positive acute myeloid leukemia (PMID: 26811524; NCT00091234).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 756,
                "therapyName": "Gemtuzumab ozogamicin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9978,
                    "pubMedId": 26811524,
                    "title": "Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26811524"
                },
                {
                    "id": 15537,
                    "pubMedId": null,
                    "title": "Mylotarg (gemtuzumab ozogamicin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13537,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Mylotarg (gemtuzumab ozogamicin) is included in guidelines for patients with CD33-positive relapsed or refractory acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 756,
                "therapyName": "Gemtuzumab ozogamicin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12026,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, treatment with fractionated doses of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia demonstrated safety and resulted in an overall response rate of 33% (19/57), with complete remission (CR) in 26% (15/57), and a median relapse-free survival of 11.6 months in patients achieving CR (PMID: 17051246).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 756,
                "therapyName": "Gemtuzumab ozogamicin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9979,
                    "pubMedId": 17051246,
                    "title": "High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17051246"
                },
                {
                    "id": 15537,
                    "pubMedId": null,
                    "title": "Mylotarg (gemtuzumab ozogamicin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12705,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Vadastuximab talirine demonstrated preliminary activity in patients with CD33-positive acute myeloid leukemia, resulting in a complete remission rate of 28% (5/18; 3 complete remissions (CR) and 2 complete remissions with incomplete hematologic recovery (CRi)) at the recommended 40mcg/kg dose (PMID: 29196412; NCT01902329).",
            "molecularProfile": {
                "id": 27618,
                "profileName": "CD33 positive"
            },
            "therapy": {
                "id": 6594,
                "therapyName": "Vadastuximab talirine",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10608,
                    "pubMedId": 29196412,
                    "title": "A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29196412"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12704,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia cells harboring FLT3-ITD mutations demonstrated increased CD33 expression, and showed increased sensitivity to IMGN779 compared to FLT3 wild-type patient cells in culture (Blood 2014 124:2321).",
            "molecularProfile": {
                "id": 28842,
                "profileName": "CD33 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 6596,
                "therapyName": "IMGN779",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10612,
                    "pubMedId": null,
                    "title": "The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations",
                    "url": "http://www.bloodjournal.org/content/124/21/2321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27618,
            "profileName": "CD33 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28842,
            "profileName": "CD33 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}